Coles R, Kushnir MM, Nelson GJ, McMillin GA, Urry FM
This was a review paper
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: A plain language summary of the ENZAMET trial (ANZUP 1304) Future Oncol
Artesunate suppresses the growth of lung cancer cells by downregulating the AKT/survivin signaling pathway
However, approval is conditional: adolescents must have severe obesity (BMI 35 or 95th percentile for age) and documented cardiovascular or metabolic complications such as type 2 diabetes, hypertension, or sleep apnea
Board-certified obesity and anti-aging specialists On-site phlebotomy, DEXA, and ultrasound to track visceral-fat changes Compounded peptides from FDA-registered 503B pharmacies Integrated programs that layer GLP-1, body-contouring, and nutrition coaching for synergistic outcomes 10